Storia in 3 fonti

Lilly puts its stamp at EHA with Jaypirca combo data in CLL, first clinical data from Ajax buyout

Eli Lilly made a push in blood cancer at this year’s European Hematology Association presenting data for Jaypirca as well as its first-ever clinical trial results in myelofibrosis.

Raccontata da

endpoints.news

fiercepharma.com

benzinga.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo1 g fa

Lilly puts its stamp at EHA with Jaypirca combo data in CLL, first clinical data from Ajax buyout

Eli Lilly made a push in blood cancer at this year’s European Hematology Association presenting data for Jaypirca as well as its first-ever clinical trial results in myelofibrosis.

originale

benzinga.com1 g fa

Eli Lilly Eyes Label Expansion For Leukemia Drug - Eli Lilly (NYSE:LLY)

Eli Lilly announces BRUIN CLL-322 success: Jaypirca added to venetoclax and rituximab reduces progression-or-death risk by 45% in relapsed or refractory CLL/SLL. The company plans to seek regulatory label expansion and pursue additional Phase 3 trials, extending therapeutic options for patients with prior BTK-inhibitor exposure.

Lilly puts its stamp at EHA with Jaypirca combo data in CLL, first clinical data from Ajax buyout

Confronto fonti

Lilly puts its stamp at EHA with Jaypirca combo data in CLL, first clinical data from Ajax buyout

Eli Lilly Eyes Label Expansion For Leukemia Drug - Eli Lilly (NYSE:LLY)

Timeline cronologica

Lilly puts its stamp at EHA with Jaypirca combo data in CLL, first clinical data from Ajax buyout

Lilly oncology chief went from ‘extremely nervous’ to ‘blown away’ by new Jaypirca CLL data

Lilly oncology chief went from ‘extremely nervous’ to ‘blown away’ by new Jaypirca CLL data

Eli Lilly Eyes Label Expansion For Leukemia Drug - Eli Lilly (NYSE:LLY)